The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
Study Details
Study Description
Brief Summary
This is an open-label, pilot trial to test the safety and efficacy of transplantation of livers from Hepatitis C seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative recipients on the liver transplant waitlist. Treatment and prophylaxis will be administered, using a transmission-triggered approach for the first scenario (HCV Ab+/NAT- donors, arm 1) and a prophylaxis approach for the later scenario (HCV Ab+/NAT+ donors, arm 2).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
This is a prospective, single center, pilot, open-label study of transplantation of livers of HCVAb+ donors to HCVAb- recipients with subsequent therapy with sofosbuvir/velpatasvir (Epclusa®). Recipients of a liver from HCVAb+/NAT- donors will be in arm 1 (the transmission-triggered arm) of the study. In this arm, the study will monitor transmission of HCV by measuring HCV RNA in liver transplant recipients. If HCV RNA is detected, indicating transmission of HCV, recipients will be treated with sofosbuvir/velpatasvir (Epclusa®) for 12 weeks. Virological response will be assessed at 4 weeks, end of treatment and 12 weeks after completion of therapy.
Recipients of a liver from HCVAb+/NAT+ donors will be in arm 2 (the prophylaxis arm) of the study. In this arm, patients will be started on a 12-week course of sofosbuvir/velpatasvir (Epclusa®) immediately post-operatively and will undergo close monitoring of HCV RNA for evidence of transmission.
To be eligible for the study, subjects need to be listed for liver transplantation, be not infected with HCV, HBV or HIV, and sign informed consent.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: HCV seropositive non-viremic (HCV Ab+/NAT-) donor Liver recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated. Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg). |
Drug: sofosbuvir/velpatasvir
12 week, oral, fixed dose
Other Names:
|
| Experimental: HCV seropositive viremic (HCV Ab+/NAT+) donor Post-operative day 1, liver recipients will be treated with 12-week oral course of sofosbuvir/ velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg). |
Drug: sofosbuvir/velpatasvir
12 week, oral, fixed dose
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Adverse events [5 years]
Rate of adverse events due to sofosbuvir/velpatasvir (Epclusa) in study participants in each experimental group
- HCV free at 1 year [1 year]
Proportion of participants in each experimental group who are free of HCV at 1 year following transplantation
Secondary Outcome Measures
- Transmission rate of HCV from HCVAb+/NAT- donors to HCVAb- recipients [5 years]
- Incidence of allograft rejection [5 years]
- Incidence of graft loss [5 years]
- All-cause mortality [5 years]
- Waitlist time after enrollment [5 years]
Eligibility Criteria
Criteria
Inclusion criteria (recipients):
-
Patients with end-stage liver disease listed for liver transplantation at UPMC.
-
Age ≥ 18
-
No available living liver donor
-
Listed for an isolated liver transplant at UPMC
-
Have panel reactive antibody level of <98%
-
Able to travel to UPMC for routine post-transplant visits and study visits for a minimum of 12 months after transplantation
-
Able to provide informed consent
-
Be willing to use a contraceptive method for a year after transplant
Exclusion criteria (recipients):
-
HIV positive
-
HCVAb or HCV RNA positive
-
Presence of behavioral risk factors for contracting HCV. These behavioral risk factors are current injection drug use, current intranasal illicit drug use, current percutaneous/parenteral exposures in an unregulated setting.
-
Hepatitis B surface antigen positive
-
History of atrial fibrillation requiring the use of amiodarone over the past 12m
-
Receipt of prior organ transplant
-
Waitlisted for a multi-organ transplant
-
Pregnant women
-
Known allergy to sofosbuvir/velpatasvir
-
Any condition, psychiatric or physical, that in the opinion of the investigator would make it unsafe to proceed with transplantation or interfere with the ability of the subject to participate in the study
Inclusion criteria (donors):
-
HCV antibody positive
-
HCV NAT negative or positive
Exclusion criteria (donors):
-
Confirmed HIV positive (positive HIV-1 antibody, positive HIV-2 antibody, positive p24 antigen and/or positive HIV NAT)
-
Confirmed HBV positive (positive hepatitis B surface antigen and/or HBV NAT)
-
Known ongoing therapy for HCV
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UPMC | Pittsburgh | Pennsylvania | United States | 15213 |
Sponsors and Collaborators
- Naudia Jonassaint
- University of Pittsburgh Medical Center
Investigators
- Study Director: Fernanda Silviera, MD, University of Pittsburgh
- Principal Investigator: Naudia Jonassaint, MD, University of Pittsburgh
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY19100082